Literature DB >> 15617949

Blinding decreased recruitment in a prevention trial of postmenopausal hormone therapy.

Elina Hemminki1, Sirpa-Liisa Hovi, Piret Veerus, Tiina Sevón, Risto Tuimala, Mati Rahu, Matti Hakama.   

Abstract

PURPOSE: To compare the effect of blind design (active drug and placebo) and nonblind design (active drug and no treatment) on recruitment.
SETTING: A primary prevention trial with postmenopausal hormone therapy in Estonia.
METHODS: Women who were eligible and willing to participate on the basis of the questionnaire survey were randomized into blind and nonblind groups. Recruitment rates are based on record keeping, and reasons for participating were requested in the first-year follow-up.
RESULTS: The recruitment was 30% higher in the nonblind group: of the 4,295 women invited, 37% (95% confidence interval CI=35-39%) in the blind group and 48% (95% CI=46-49%) in the nonblind group were recruited. In both groups, once randomized, most of the losses were women who did not attend the first clinical examination: 49% (blind; 95% CI=47-51%) and 40% (nonblind; 95% CI=38-42%). The rest were found ineligible or lost their interest during clinical examinations. The reasons for joining the trial were relatively similar in the two groups.
CONCLUSIONS: Blinding decreased women's interest in joining a long-term preventive trial. Women's reasons for joining the trial were not influenced by blinding.

Entities:  

Mesh:

Year:  2004        PMID: 15617949     DOI: 10.1016/j.jclinepi.2004.04.009

Source DB:  PubMed          Journal:  J Clin Epidemiol        ISSN: 0895-4356            Impact factor:   6.437


  9 in total

Review 1.  Strategies for increasing recruitment to randomised controlled trials: systematic review.

Authors:  Patrina H Y Caldwell; Sana Hamilton; Alvin Tan; Jonathan C Craig
Journal:  PLoS Med       Date:  2010-11-09       Impact factor: 11.069

2.  Results from a blind and a non-blind randomised trial run in parallel: experience from the Estonian Postmenopausal Hormone Therapy (EPHT) Trial.

Authors:  Piret Veerus; Krista Fischer; Matti Hakama; Elina Hemminki
Journal:  BMC Med Res Methodol       Date:  2012-04-04       Impact factor: 4.615

Review 3.  Strategies to improve recruitment to randomised trials.

Authors:  Shaun Treweek; Marie Pitkethly; Jonathan Cook; Cynthia Fraser; Elizabeth Mitchell; Frank Sullivan; Catherine Jackson; Tyna K Taskila; Heidi Gardner
Journal:  Cochrane Database Syst Rev       Date:  2018-02-22

4.  Experiences of a long-term randomized controlled prevention trial in a maiden environment: Estonian Postmenopausal Hormone Therapy trial.

Authors:  Sirpa-Liisa Hovi; Piret Veerus; Mati Rahu; Elina Hemminki
Journal:  BMC Med Res Methodol       Date:  2008-08-01       Impact factor: 4.615

Review 5.  Increasing recruitment to randomised trials: a review of randomised controlled trials.

Authors:  Judith M Watson; David J Torgerson
Journal:  BMC Med Res Methodol       Date:  2006-07-19       Impact factor: 4.615

6.  Effect of characteristics of women on attendance in blind and non-blind randomised trials: analysis of recruitment data from the EPHT Trial.

Authors:  Piret Veerus; Krista Fischer; Elina Hemminki; Sirpa-Liisa Hovi; Matti Hakama
Journal:  BMJ Open       Date:  2016-10-18       Impact factor: 2.692

Review 7.  Blinding in Clinical Trials: Seeing the Big Picture.

Authors:  Thomas F Monaghan; Christina W Agudelo; Syed N Rahman; Alan J Wein; Jason M Lazar; Karel Everaert; Roger R Dmochowski
Journal:  Medicina (Kaunas)       Date:  2021-06-24       Impact factor: 2.430

8.  Methods to improve recruitment to randomised controlled trials: Cochrane systematic review and meta-analysis.

Authors:  Shaun Treweek; Pauline Lockhart; Marie Pitkethly; Jonathan A Cook; Monica Kjeldstrøm; Marit Johansen; Taina K Taskila; Frank M Sullivan; Sue Wilson; Catherine Jackson; Ritu Jones; Elizabeth D Mitchell
Journal:  BMJ Open       Date:  2013-02-07       Impact factor: 2.692

9.  Guidelines for reporting embedded recruitment trials.

Authors:  Vichithranie W Madurasinghe
Journal:  Trials       Date:  2016-01-14       Impact factor: 2.279

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.